174 related articles for article (PubMed ID: 1405382)
1. Use of alkaline calcium salts as phosphate binder in uremic patients.
Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
6. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
7. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
8. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
[TBL] [Abstract][Full Text] [Related]
9. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
10. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
11. Calcium balance and intact PTH variations during haemodiafiltration.
Argilés A; Mion CM
Nephrol Dial Transplant; 1995 Nov; 10(11):2083-9. PubMed ID: 8643172
[TBL] [Abstract][Full Text] [Related]
12. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
Fournier A; Morinière P; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephrologie; 1995; 16(2):165-90. PubMed ID: 7753302
[TBL] [Abstract][Full Text] [Related]
13. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
[TBL] [Abstract][Full Text] [Related]
14. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
[TBL] [Abstract][Full Text] [Related]
15. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
16. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
Sánchez Perales MC; García Cortés MJ; Borrego FJ; Fernández Martínez S; Borrego J; Pérez del Barrio P; Liébana A; Pérez Bañasco V
Nefrologia; 2000; 20(3):254-61. PubMed ID: 10917002
[TBL] [Abstract][Full Text] [Related]
17. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
19. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
20. [Control of calcium and phosphate metabolism and prevention of vascular calcifications in uremic patients].
Malberti F; Ravani P
G Ital Nefrol; 2005; 22 Suppl 31():S47-52. PubMed ID: 15786402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
